Andrew S. Robertson

Learn More
Diseases such as trypanosomiasis, leish-maniasis, and lymphatic filariasis impose substantial health burdens in developing countries [1,2]. These diseases are widely neglected because there is little financial incentive for biopharmaceutical companies to invest in developing new treatments , vaccines, and diagnostics. Most of the 1,000,000,000 people(More)
The need for new drugs and vaccines for neglected tropical diseases (NTDs) is widely accepted [1]. Yet, encouraging pharmaceutical and biotechnology company investment in developing these much-needed treatments remains a challenge due to a lack of a commercial market driving companies to pursue NTD projects [2]. To address this challenge, economists Ridley,(More)
BACKGROUND Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa. OBJECTIVE To compare BMD change in men receiving either(More)
Amici are scholars with the Information Society Project at Yale Law School (ISP), 2 an intellectual center addressing the implications of new information technologies for law and society: Wendy Seltzer, a Senior Fellow at the ISP, writes on law and technology of free expression and user innovation, including digital copyright, software patent, and(More)
Acknowledgement I would like to thank my advisor, Richard Andersen, for the opportunity to do this work, and for his guidance and the excellent laboratory environment he has provided. I would also like to thank my committee, Cui, and Yaser Abu-Mostafa for many productive and enjoyable discussions. I also feel very grateful for support from the Sloan Swartz(More)
Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and(More)
The management of castrate-resistant prostate cancer progressing after maximum androgen blockade (MAB) has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patients usually involves withdrawal of anti-androgen that can be associated with biochemical response in(More)
  • 1